Agency Business briefs

Share this article:

Drumbeat Digital's LA outpost, Heartbeat West, is moving to a larger space in Santa Monica and getting new leadership. The shop, which opened in July, will be led by Janelle Starr, who joins from the firm's New York headquarters as SVP general manager of Heartbeat West.

Ogilvy PR acquired a majority stake in Hong Kong-based healthcare communications shop Mind Resource Healthcare Consulting Limited, giving Ogilvy entrée into the $600 million Hong Kong healthcare advertising market.

Healthcare PR company GCI Health expanded into Chicago. The new office, WPP's only health PR shop in the City of Big Shoulders, will be staffed by GCI Health execs and overseen from afar by CEO Wendy Lund, based in New York.

Boonton, NJ-based boutique health PR shop Green Room Public Relations has expanded with a Cambridge, MA office. The shop's second office, it will be overseen by partners Karen Carolonza and Deborah Sittig, and will be staffed through a model “which combines full time employees and independent industry veterans to create customized, skill-based client teams.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?